ライフサイエンスコーパス: headache

1 ted to treatment occurred in the ISAT group (headache).

2 e, may be a preventive treatment for cluster headache.

3 migraine-like headache and tension-type-like headache.

4 stimulation for treatment of chronic cluster headache.

5 approach to the treatment of chronic cluster headache.

6 ic to chronic headache or medication overuse headache.

7 adache is the most disabling form of cluster headache.

8 vailable guidelines for migraine and cluster headache.

9 dominant clinical finding is an orthostatic headache.

10 e most common drug-related adverse event was headache.

11 AH in a premenopausal woman presenting with headache.

12 action of fremanezumab in the prevention of headache.

13 ate pain at the injection site, fatigue, and headache.

14 s a neural substrate for ictal and postictal headache.

15 help reduce the burden of medication overuse headache.

16 enza, upper respiratory tract infection, and headache.

17 are common in both migraine and non-migraine headaches.

18 o CAD was inversely associated with migraine headaches.

19 and duration of ictal and possibly postictal headaches.

20 th tinnitus (n = 660) or without (n = 1,879) headaches.

21 about the pathophysiology of seizure-induced headaches.

22 included new or increased cough (2 points), headache (1 point), subjective fever (1 point), and tria

23 common adverse events with solriamfetol were headache (10.1%), nausea (7.9%), decreased appetite (7.6

24 Fatigue (11 [13%] patients) and headache (11 [13%]) were the only adverse events that oc

25 74 participants who received ABI-H0731 were headache (11 [15%]), influenza-like illness (seven [9%])

26 most common drug-related adverse events were headache (11 participants in the early-switch group [2%]

27 9.9% vs 1.1%), hypotension (8.8% vs 0%), and headache (11% vs 6.7%) TEAEs with praliciguat compared w

28 fection (15 [5%] vs 15 [5%] vs 11 [4%]), and headache (12 [4%] vs 17 [6%] vs 11 [4%]).

29 st common adverse events were fatigue (25%), headache (13%), upper respiratory tract infection (8%),

30 monly dizziness (23.1%), somnolence (16.5%), headache (14.0%).

31 Common triggers were: migraine/severe headache (15), stroke (12), surgery or injury to mouth o

32 rse events were nausea (39 [7%] vs 18 [7%]), headache (16 [3%] vs 12 [5%]), and dizziness (12 [2%] vs

33 mos (61%), diminished visual acuity (77.8%), headache (16.7%), and intracerebral haemorrhage (5.55%),

34 The most common adverse events were headache (17 [8%] participants in the BUP-XR 300 mg/300

35 The most prevalent symptoms were headaches (171), near vision problems (149) and reduced

36 tory tract infection (36 [10%] patients) and headache (18 [5%] patients).

37 Headache (1832 [25.4%]), fatigue (1361 [18.9%]), and mus

38 >=5% across all solriamfetol doses included headache (21.5%), nausea (10.7%), decreased appetite (10

39 eported adverse events were nausea (27%) and headache (23%).

40 n the 94 patients were nausea (30 [32%]) and headache (26 [28%]).

41 reactogenic events were fatigue (29 [43%]), headache (26 [39%]), and malaise (15 [22%]).

42 25%), worsening renal function (21% vs 20%), headache (26% vs 10%), dizziness (15% vs 10%), and hypot

43 patients), musculoskeletal pain (303 [38%]), headache (278 [35%]), depression (124 [17%] of 713 respo

44 aged 6 to <12 years were vomiting (32%) and headache (29%), and those in patients aged 3 to <6 years

45 Most frequent adverse events were headaches (4%) and skin reactions (3%).

46 roup), diarrhoea (48 [15%] vs 50 [16%]), and headache (41 [13%] vs 51 [16%]).

47 ological symptoms were encephalopathy (57%), headache (42%), tremor (38%), aphasia (35%) and focal we

48 ontrols: urinary frequency (14.7% vs. 3.4%), headache (47.6% vs. 35.6%), fatigue (18.4% vs. 6.3%), mu

49 peripheral blood smear (36%), fatigue (64%), headaches (50%), fever (45%), chills (45%), hyperbilirub

50 [16%] of 325 in the dolutegravir group) and headache (51 [16%] of 320 vs 48 [15%] of 325).

51 erosis relapses (117 [36%] vs 30 [32%]), and headache (51 [16%] vs 23 [25%]).

52 e, and were most commonly diarrhea (52%) and headache (51%).

53 Overall, the most common adverse events were headache (55 [23%] of 240), fatigue (47 [20%] of 240), a

54 navir group), nausea (45 [12%] vs 52 [14%]), headache (57 [15%] vs 46 [12%]), and upper respiratory t

55 , Ad26.ZEBOV, and placebo, respectively) and headache (57%, 56%, and 46%, respectively).

56 uent adverse effects among 173 patients were headache (61 [35%] patients), back pain (38 [22%]), and

57 th RHB-105 vs. 7.9% with active comparator), headache (7.5% vs. 7.0%), and nausea (4.8% vs. 5.3%).

58 adverse events were hypertension (97 [32%]), headache (78 [26%]), dizziness (61 [20%]), and fatigue (

59 le and had lower CSF opening pressure, fewer headaches, a higher chance of incidentally identified pa

60 kly frequency of attacks of episodic cluster headache across weeks 1 through 3 after the initial inje

61 Six (46%) participants experienced headache, all deemed unrelated to treatment.

62 Six (46%) subjects experienced headache; all deemed unrelated to treatment.

63 We studied 60 people: 20 without headache and 20 each with interictal photophobia from mi

64 (3.8%) experienced the adverse event of mild headache and 3 (2.8%) discontinued scalp cooling due to

65 n and were transient; 92% of the episodes of headache and 47% of the episodes of insomnia resolved wi

66 The most common drug-related adverse events, headache and an elevated lactate dehydrogenase level, oc

67 rder, characterized by attacks of unilateral headache and by global dysfunction in multisensory infor

68 ears with chronic migraine, enrolled from 69 headache and clinical research centres in North America

69 y present with nonspecific symptoms, such as headache and cognitive impairment, but might also experi

70 ensitization potentially mediating throbbing headache and cranial allodynia.

71 l presentation runs a spectrum, ranging from headache and dizziness to coma and death, with a mortali

72 History A 53-year-old man experienced headache and double vision that progressed over 1 year.

73 The most common AEs were headache and fatigue, occurring at similar frequencies w

74 rder, characterized by attacks of unilateral headache and global dysfunction in multisensory informat

75 Although migraine is defined by the headache and headache-associated symptoms, the true begi

76 Headache and increased heart rate were increased on levo

77 Common adverse events, including headache and insomnia, occurred at the time of drug init

78 19 and later developed an acute-onset severe headache and loss of consciousness and was diagnosed wit

79 bit neurological manifestations ranging from headache and loss of smell, to confusion and disabling s

80 y clinical areas, including several (such as headache and low back pain) commonly encountered by inte

81 induced urticarial rash, arthralgia, chills, headache and malaise associated with an autosomal-domina

82 The most common adverse events were headache and nasopharyngitis.

83 ) can develop neurological sequelae, such as headache and neuroinflammatory or cerebrovascular diseas

84 ychological characteristics differed between headache and non-headache subjects with any tinnitus.

85 of appetite related to nausea and vomiting, headache and significant malaise.

86 The most common TEAEs were headache and somnolence and nearly all TEAEs were mild i

87 most common PTH phenotypes are migraine-like headache and tension-type-like headache.

88 The most common adverse events were headache and upper respiratory tract infection.

89 Veterans with GWI related chronic headaches and body pain (N = 20, all males) had a signif

90 In cases of asthenopia, such as headaches and loss of concentration, associated with nea

91 ds to human use and may explain why fatigue, headaches and nervousness have been reported as side eff

92 with neurological symptoms, including severe headaches and sensory or motor deficits, often as a cons

93 for alleviating occipital than non-occipital headaches and that occipital migraines may be associated

94 oject to i) evaluate the association between headaches and tinnitus (n = 1,984 cases and 1,661 contro

95 er) in MWA patients (n = 11) who experienced headaches and visual aura in the preceding month.

96 , is responsible for conditions as benign as headaches and vomiting or as severe as seizures, neurolo

97 esented with a three-week history of frontal headache, and 'blurriness' in the left side of her visio

98 he reported additional symptoms of weakness, headache, and arthralgia primarily involving her bilater

99 as development and nasal and sinus, migraine headache, and fatigue symptoms in Pennsylvania.

100 migraine drugs can increase the frequency of headache, and induce the transition from episodic to chr

101 verse events included hypertension, fatigue, headache, and irregular menstruation.

102 Anaplasmosis presents with fever, headache, and laboratory abnormalities including leukope

103 vesiculopustular rash, and fever, pruritus, headache, and lymphadenopathy were also common.

104 a leakage, manifesting as nonspecific fever, headache, and maculopapular rash.

105 pain, feeling feverish, chills, muscle ache, headache, and malaise (all p<0.05).

106 d as return to usual activities, with fever, headache, and muscle ache minor or absent.

107 grade 1 to 2 adverse events were bone pain, headache, and myalgia.

108 le (common adverse events: nausea, diarrhea, headache, and nasopharyngitis).

109 Male sex, migraine headache, and prior sinus surgery were associated with h

110 nitiation and maintenance of seizure-induced headache, and that their activation patterns can provide

111 e, cyanosis, venous dilatation, paresthesia, headache, and tinnitus) in the setting of extreme erythr

112 2010 when she was evaluated for intractable headaches, and electroencephalography revealed her focal

113 mnia, akathisia, worsening of schizophrenia, headache, anxiety) were reported in 123 (54%) patients t

114 odulation therapies for migraine and cluster headache are a practical and safe alternative to pharmac

115 such headaches; the first suggests that the headaches are caused by spasm or tension of scalp, shoul

116 l migraines.SIGNIFICANCE STATEMENT Occipital headaches are common in both migraine and non-migraine h

117 gion, whereas the second suggests that these headaches are initiated by activation of meningeal nocic

118 mmon side effects included fatigue, myalgia, headache, arthralgia and fever.

119 mmon side effects included fatigue, myalgia, headache, arthralgia, and fever.

120 re commonly absent or mild in severity, with headaches as the leading complaint (n = 13 of 16).

121 ; and it is unclear which receptors regulate headache associated symptoms.

122 ough migraine is defined by the headache and headache-associated symptoms, the true beginning of a mi

123 we found a significant 77% mean reduction in headache attack frequency over a mean follow-up of 44 mo

124 baseline in the weekly frequency of cluster headache attacks across weeks 1 through 3 after receipt

125 reduction in the weekly frequency of cluster headache attacks across weeks 1 through 3 was 8.7 attack

126 least 50% in the weekly frequency of cluster headache attacks at week 3.

127 The mean (+/-SD) number of cluster headache attacks per week in the baseline period was 17.

128 ache, who reported a minimum of four cluster headache attacks per week that were unsuccessfully contr

129 ogic disorder that is characterized by daily headache attacks that occur over periods of weeks or mon

130 ent of short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing

131 act in short lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing

132 T) and short-lasting unilateral neuralgiform headache attacks with cranial autonomic symptoms (SUNA)

133 aps in short lasting unilateral neuralgiform headache attacks with cranial autonomic symptoms (SUNA).

134 to reduce the intake of medication for acute headache attacks.

135 The pattern was slightly different for headache (baseline, RR = 3.44; 12 months, RR = 3.26), du

136 atment AEs were respiratory tract infection, headache, bronchitis, and asthma worsening.

137 on-site pain, feeling feverish, muscle ache, headache), but were less common in older adults (aged >=

138 practice of attempting to alleviate migraine headaches by targeting the greater and lesser occipital

139 atment option for refractory chronic cluster headache (CCH).

140 of patients seen between 2007 and 2017 in a headache centre and diagnosed with PTH-CH that developed

141 ouble-blind, safety and efficacy study at 21 headache centres in the USA.

142 including coronary artery disease, migraine headache, cervical artery dissection, fibromuscular dysp

143 Adverse events were infrequent and included headache, chest pressure, and orthostatic symptoms.

144 thout any history of trauma who attended the headache clinic during the same period.

145 AEs of nausea, headache, constipation, dizziness, and somnolence, each

146 Our study suggests that headaches could contribute to tinnitus distress and pote

147 oup had a significantly greater reduction in headache days (-3.4 vs. -2.0 days/month, p = 0.025).

148 The mean number of baseline headache days (as defined above) per month was 13.2, 12.

149 hange from baseline in the average number of headache days (defined as days in which headache pain la

150 t was associated with sustained reduction in headache days and PHQ-9 and GAD-7 scores in the analysis

151 up had on average 4.1 fewer monthly migraine headache days compared with baseline (13.4), while the p

152 from baseline in number of monthly migraine headache days during the 3-month treatment period in all

153 >=50%, >=75% and 100% reduction in migraine headache days from baseline at months 1, 2 and 3 were ca

154 ve reduction of 50% or more in the number of headache days in the comparison of the 28-day baseline p

155 anezumab) vs -0.53+/-0.11 (placebo) migraine headache days indicated onset at week 1.

156 h; chronic migraine, at least eight migraine headache days per month and at least 15 headache days pe

157 ency episodic migraine, eight to 14 migraine headache days per month and fewer than 15 headache days

158 aine headache days per month and at least 15 headache days per month).

159 ne headache days per month and fewer than 15 headache days per month; chronic migraine, at least eigh

160 migraine, four to fewer than eight migraine headache days per month; high frequency episodic migrain

161 The number of migraine headache days per week, and onset of efficacy measured a

162 significantly greater reduction in migraine headache days versus placebo across months 1-3.

163 Reversible delirium, headache, decreased level of consciousness, tremor, and

164 a simple Markov model of migraine attacks on headache diary data and estimated transition probabiliti

165 adache (PTH) is a highly disabling secondary headache disorder and one of the most common sequelae of

166 schaemic heart disease, Alzheimer's disease, headache disorder, and low back pain.

167 identified as a novel therapeutic target for headache disorders and migraine.

168 similarities and differences between primary headache disorders and PTH could uncover unique treatmen

169 f vagus nerve stimulation as a treatment for headache disorders.

170 verlap exists between PTH and common primary headache disorders.

171 identified as a promising novel therapy for headache disorders.

172 The most common AEs reported were headache, dizziness, abdominal pain, fever, nausea, and

173 on adverse events in the SAGE-217 group were headache, dizziness, nausea, and somnolence.

174 sitivity C-reactive protein at 1 year; fewer headaches, dizziness, or cramps; and shorter postdialysi

175 An epileptic seizure can trigger a headache during (ictal) or after (postictal) the termina

176 gitis, worsening of nasal polyps and asthma, headache, epistaxis, and injection-site erythema) were m

177 al period, 21 of 30 patients (70%) developed headache exacerbation with migraine-like features after

178 ing outcomes: (1) difference in incidence of headache exacerbation with migraine-like features and (2

179 ng to the emergency department for a frontal headache, eye pain, emesis, and lethargy.

180 ent understanding of the origin of occipital headache falls short of distinguishing between cause and

181 d to moderate adverse events reported (e.g., headache, fatigue).

182 irways leading to dry cough, fever, myalgia, headache, fatigue, and diarrhea and can end up in inters

183 vidual gastrointestinal symptoms, as well as headaches, fatigue, and dizziness.

184 vent; the most common systemic symptoms were headache (five [20%] with 0.67 mg, 11 [44%] with 2 mg, a

185 that people with migraine do not differ from headache-free controls in the manner in which melanopsin

186 task in 29 episodic migraine patients and 41 headache-free controls.

187 ients who had a reduction of at least 50% in headache frequency at week 3 was 71% in the galcanezumab

188 In addition to reducing headache frequency, onabotulinumtoxinA treatment for CM

189 requent solicited systemic adverse event was headache (frequency, 50%, 61%, and 42% per dose for MVA-

190 Treatment of medication overuse headache has three components.

191 Headaches have been related to tinnitus, yet little is k

192 to 1.0 for abdominal pain, nonspecific pain, headache, hypotension/syncope, tachycardia (including po

193 ated to tinnitus, yet little is known on how headaches impact tinnitus.

194 ioid induced hyperalgesia/medication overuse headache in Dlx-DOR conditional knockouts.

195 odynia was triggered alongside migraine-like headache in nearly half of subjects.

196 causes behavioral responses consistent with headache in preclinical rodent models.

197 , RR = 3.26), due to increased prevalence of headache in those without mTBI.

198 ss in four participants (50%) and malaise or headache in three (38%) participants.

199 common reason for imaging was due to chronic headaches in 62.5% of cases and 44.3% of controls.

200 ed with 6.8% of those in the placebo group), headache (in 25.1% and 31.9%, vs. 16.9%), muscle pain (i

201 adverse event, the most common of which were headache (in 45 [16%] given mepolizumab vs 59 [21%] give

202 ommon (n>1) drug-related adverse events were headache (in nine [30%] participants) and diarrhoea (in

203 one [8%] of 12 and in five [14%] of 36), and headaches (in none and in five [14%] of 36).

204 ght to be associated with medication overuse headache, including opioids and triptans.

205 These alterations may contribute to headache, increased sensory gain, and sensory processing

206 balance as mechanisms that may contribute to headache, increased sensory gain, and sensory processing

207 or less than 50% improvement of the migraine headache index (MHI) after surgery.

208 used to treat asthma, bronchitis, diarrhea, headache, inflammation and cardiac disorders.

209 The most common adverse reactions include headache, insomnia and nausea.

210 diarrhoea, vomiting, nasopharyngitis, falls, headache, insomnia, and anxiety.

211 eported adverse events were fatigue, nausea, headache, insomnia, and rash.

212 baseline-corrected area under the curve for headache intensity scores was significantly larger after

213 d (2) difference in area under the curve for headache intensity scores.

214 eness; Short Run Low Grey Level Emphasis and Headaches, Inverse Difference Moment and Trabecular Sepa

215 de: 1/125; ferric carboxymaltose: 8/117) and headache (iron isomaltoside: 4/125; ferric carboxymaltos

216 Episodic cluster headache is a disabling neurologic disorder that is char

217 Medication overuse headache is estimated to affect 2% of the population, an

218 Medication overuse headache is more common in women and in people with como

219 Chronic cluster headache is the most disabling form of cluster headache.

220 Headache, joint problems, diarrhea, and lymphadenopathy

221 mptom, 13%, 10%, 8%, and 6% experienced more headache, joint problems, diarrhea, and lymphadenopathy,

222 patients with normal blood counts, but with headaches, lethargy, or abdominal pain, reported symptom

223 e the first to demonstrate that CGRP-induced headache-like behavioral responses at doses up to 3.8 mu

224 Hypothesizing that occipital headache may involve activation of meningeal nociceptors

225 GSK2245035 induced CytoRS-AEs (most commonly headache, median duration <1 day) in 93% of participants

226 77 age- and sex-matched individuals free of headache/migraine.

227 iveness of the DOR agonist SNC80 in multiple headache models.

228 with GWI related diffuse body pain including headache, muscle and joint pain with their military coun

229 nd most frequently included fatigue, chills, headache, myalgia, and pain at the injection site.

230 f the participants included fatigue, chills, headache, myalgia, and pain at the injection site.

231 ation preceded admission with a sore throat, headache, myalgia, and pyrexia.

232 mbosis (n = 3), cerebral infarction (n = 2), headache (n = 2), and myelofibrosis (n = 2) occurred in

233 85%-93%]; LR, 0.16 [95% CI, 0.06-0.64]), or headache (n = 323; sensitivity, 3% [95% CI, 0%-7%]; spec

234 on and a diseased control group with cluster headache (n = 35).

235 llulitis (n=1 [2%]), pneumonitis (n=1 [2%]), headache (n=1 [2%]), lung infection (n=1 [2%]), skin inf

236 =334)-fever (n=333), leukopenia (n=217), and headache (n=203) were most common and peaked within 3 da

237 . controls: n = 60 [92.3%]; P = .045), fewer headaches (n = 33 [50.8%] vs. controls: 52 [80.0%]; P =

238 Headache, nausea, and fatigue were also more common amon

239 RMSF clinical signs generally include fever, headache, nausea, vomiting, muscle pain, lack of appetit

240 by a screener, which we validated against a headache neurologist.

241 One adverse event (mild headache, not requiring medication) was considered possi

242 Headache occurred in 16.7% of patients during levosimend

243 d patients with chronic migraine (defined as headache of any duration or severity on >/=15 days per m

244 ion [triptans or ergots] was used to treat a headache of any severity or duration) per month during t

245 ch medication, if any, to use to prevent the headache of pediatric migraine has not been established.

246 therapeutic benefit of CGRP-mAb in reducing headaches of intracranial origin such as migraine with a

247 nding questions about the pathophysiology of headaches of intracranial origin.

248 was present within the last 48 hours before headache onset but not earlier.

249 e or myalgia in three (18%) participants and headache or chills in two (12%) participants.

250 duce the transition from episodic to chronic headache or medication overuse headache.

251 Observed systemic AEs were mostly headache or myalgia, and local AEs were application-site

252 ne theory will explain all types of migraine headache or the mechanisms of action of drugs that preve

253 en who gave birth also reported more chronic headaches or migraines and joint pain, but experienced s

254 minal, pelvic, back, and joint pain; chronic headaches or migraines; obesity; asthma; gestational and

255 was observed between the score and migraine headaches (OR: 0.94; 95% CI: 0.93 to 0.96).

256 % of survivors, with pairings of joint pain, headache, or fatigue the most frequent.

257 0% of survivors with pairings of joint pain, headache, or fatigue the most frequent.

258 severity for all symptoms ( P < .01) except headaches ( P = .054).

259 iogenin in Saliva, VE-cadherin in Saliva and Headaches, PA1 in Saliva and Headaches, PA1 in Saliva an

260 n in Saliva and Headaches, PA1 in Saliva and Headaches, PA1 in Saliva and Range of mouth opening with

261 r of headache days (defined as days in which headache pain lasted >/=4 consecutive hours and had a pe

262 ve was to assess the proportion of patients' headache pain-free and most bothersome symptom-free at 2

263 ICP) exhibit neuro-ocular symptoms including headache, papilloedema and loss of vision.

264 tients in the remission stage and in cluster headache patients, suggesting that these meningeal lymph

265 assessment, as well as a history of cluster headache periods lasting at least 6 weeks, and randomly

266 Second only to headache, photophobia is the most debilitating symptom r

267 Post-traumatic headache (PTH) is a highly disabling secondary headache

268 Headaches, Range of mouth opening without pain, Energy,

269 mized Investigation to Evaluate Incidence of Headache Reduction in Subjects With Migraine and PFO Usi

270 for the action of DOR agonists in relieving headache-related symptoms and suggest that forebrain reg

271 The underlying causes of migraine headache remained enigmatic for most of the 20th century

272 cal profiles were: fever and at least two of headache, retro-orbital pain, myalgia, arthralgia, rash,

273 highlight a differential medication overuse headache risk profile for the ditan and gepant classes o

274 legs (RR, 8.1; 95% CI, 2.5 to 26.4); severe headaches (RR, 3.2; 95% CI, 1.6 to 6.3); and prolonged a

275 baseline covariates, pre- and postoperative headache scores at median (12-month) and long-term follo

276 s [27%]), nasopharyngitis (seven [27%]), and headache (six [23%]).

277 s using recommendations of the International Headache Society for pharmacological clinical trials, th

278 s, one needs to investigate the phase before headache starts.

279 cteristics differed between headache and non-headache subjects with any tinnitus.

280 ibulo-ocular reflex (VOR) and vestibular and headache symptom severity.

281 ic migraine resulted in a lower frequency of headache than placebo in this 12-week trial.

282 eports of mild neck pain, scalp tingling and headache that were extinguished upon follow-up.

283 stinct scenarios have been proposed for such headaches; the first suggests that the headaches are cau

284 individuals report a range of symptoms from headaches to shortness of breath to taste and smell loss

285 Headache (twice-weekly treatment) and nasopharyngitis (o

286 and interactions of TGF-beta1 in Saliva and Headaches, VE-cadherin in Serum and Angiogenin in Saliva

287 n a multivariable logistic regression model, headache was significantly associated with any tinnitus

288 The incidence of postdural-puncture headache was significantly reduced from 11.0% (95% CI 9.

289 on subjects with tinnitus, the prevalence of headaches was 26% and reached 40% in subjects with sever

290 Nausea, vomiting, constipation, and headache were more common in the SXT arm.

291 Vomiting, nausea, and headache were the only treatment-emergent adverse events

292 Headaches were associated with adherence only in the pla

293 In total, 217 patients (182 RCVS, 35 cluster headache) were analyzed and separated into 2 groups base

294 Two (7%) adverse events (fatigue and headache) were deemed possibly related to treatment with

295 significantly more likely than men to report headache while older age was significantly associated wi

296 significantly more likely than men to report headache, while older age was significantly associated w

297 aged 22 years or older with chronic cluster headache, who reported a minimum of four cluster headach

298 specific guidelines for migraine and cluster headache will be soon available, but adherence to curren

299 ia, epigastric or right upper-quadrant pain, headache with visual disturbances, fetal growth restrict

300 and had a long-standing history of migraine headaches without hormonal or drug therapy.